107
107 years of development
119
Vaccine coverage over 119 countries and regions
15
15 innovative drugs under R&D
3
3 production workshops with a hundred-of-million production scale of COVID-19 Inactivated Vaccine (Vero Cell)
News Recommendation
Beijing Institute of Biological Prod
2026-08-19
BIBPthPart 1: Introduction to the Capital Science and Technology Infrastructure PlatformThe Capital Science and Technology Infrastructure Platform is a Beijing local science and technology infrastructure platform operating under the gui...
View More+
China National Biotec Group Beijing
2026-08-11
thheld The meeting pointed out that since the beginning of this year, the company has resolutely implemented various decisions and deployments from higher authorities, focused on key priorities including quality improvement, ma...
View More+
The bOPV Product of BIBP Successfull
2026-04-03
Global Business Unitparticipated in and supported the inspection process throughout. Nigeria is the most populous country in Africa. As one of the most influential pharmaceutical regulatory authorities...
View More+About Company
Beijing Institute of Biological Products Co., Ltd. (BIBP), a subsidiary of China National Biotec Group Company Limited (CNBG), China National Pharmaceutical Group Co., Ltd. (Sinopharm), is engaged in the research, production and marketing of vaccines, diagnostic preparations and other biological products, with a registered capital of CNY 2.3 billions. The history of BIBP can be traced back to 1919 when National Epidemic Prevention Bureau was established , representing the cradle of biological products for The People's Republic of China.
Achievements More+Scientific Research and Innovation
